Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 5 Early and modest immune response at day 3 after exposure in Delayed animals. Early and modest immune response at day 3 after exposure in Delayed.

Published byWinifred Claire Watts Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 5 Early and modest immune response at day 3 after exposure in Delayed animals. Early and modest immune response at day 3 after exposure in Delayed."— Presentation transcript:

1 Fig. 5 Early and modest immune response at day 3 after exposure in Delayed animals.
Early and modest immune response at day 3 after exposure in Delayed animals. Analysis of the NanoString samples with only the genes identified as being up-regulated at an early time point (day 3 after exposure, Delayed). (A) MA plot of the 178 up-regulated genes at day 3 after exposure in Delayed animals. Each point represents a gene. The x axis is the log2 of the base mean counts, and the y axis is the log2 fold change relative to day 0. (B) MA plot for the same genes at day 6 after exposure. (C) Principal components analysis (PCA) of the 178 up-regulated genes across all samples. K-means clustering was performed on all principal components with k = 3 to determine the clustering. The PCA plot is showing the first two principal components. The colors represent the different clusters. Emily Speranza et al., Sci Transl Med 2018;10:eaaq1016 Published by AAAS

Download ppt "Fig. 5 Early and modest immune response at day 3 after exposure in Delayed animals. Early and modest immune response at day 3 after exposure in Delayed."

Similar presentations

Fig. 1. Loss of circadian rhythms in iKO mice.

Fig. 1. Loss of circadian rhythms in iKO mice.
Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.

Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.
Fig. 5. Protective efficacy of the combination of PGT121 + PGDM1400 against a mixed SHIV challenge in rhesus monkeys. Protective efficacy of the combination.

Fig. 5. Protective efficacy of the combination of PGT121 + PGDM1400 against a mixed SHIV challenge in rhesus monkeys. Protective efficacy of the combination.
Fig. 2 LYM attractor metagene.

Fig. 2 LYM attractor metagene.
Fig. 6. dAST directly from clinical samples using dPCR and dLAMP for quantification. dAST directly from clinical samples using dPCR and dLAMP for quantification.

Fig. 6. dAST directly from clinical samples using dPCR and dLAMP for quantification. dAST directly from clinical samples using dPCR and dLAMP for quantification.
Fig. 5. Blocking LTB4 during initial lymphangiogenesis period abrogates the therapeutic benefit of LTB4 antagonism. Blocking LTB4 during initial lymphangiogenesis.

Fig. 5. Blocking LTB4 during initial lymphangiogenesis period abrogates the therapeutic benefit of LTB4 antagonism. Blocking LTB4 during initial lymphangiogenesis.
Fig. 4. BET bromodomain inhibition suppresses transactivation of shared transcriptional networks across HF models. BET bromodomain inhibition suppresses.

Fig. 4. BET bromodomain inhibition suppresses transactivation of shared transcriptional networks across HF models. BET bromodomain inhibition suppresses.
Fig. 1. The cell-intrinsic fibroblast circadian proteome contains numerous cytoskeletal regulators. The cell-intrinsic fibroblast circadian proteome contains.

Fig. 1. The cell-intrinsic fibroblast circadian proteome contains numerous cytoskeletal regulators. The cell-intrinsic fibroblast circadian proteome contains.
Fig. 2. Mechanism of PD-L1 down-regulation in NOD HSPCs.

Fig. 2. Mechanism of PD-L1 down-regulation in NOD HSPCs.
Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.

Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.
Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.

Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.
Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.
Fig. 4. Specific antibiotics reduce fecal biomass in mice and humans.

Fig. 4. Specific antibiotics reduce fecal biomass in mice and humans.
In vivo prophylactic and therapeutic efficacy of C12G6 in mice

In vivo prophylactic and therapeutic efficacy of C12G6 in mice
Fig. 2. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral blood. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral.

Fig. 2. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral blood. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral.
Fig. 2. dAST using dPCR is robust to the presence of high concentrations of commensal bacteria due to the specificity of NA amplification. dAST using dPCR.

Fig. 2. dAST using dPCR is robust to the presence of high concentrations of commensal bacteria due to the specificity of NA amplification. dAST using dPCR.
Fig. 5. Performance of the MGA to enable or enhance locomotor control after SCI. Performance of the MGA to enable or enhance locomotor control after SCI.

Fig. 5. Performance of the MGA to enable or enhance locomotor control after SCI. Performance of the MGA to enable or enhance locomotor control after SCI.
Fig. 6. Treatment with a DLK inhibitor is neuroprotective and reverses stress-induced gene expression changes. Treatment with a DLK inhibitor is neuroprotective.

Fig. 6. Treatment with a DLK inhibitor is neuroprotective and reverses stress-induced gene expression changes. Treatment with a DLK inhibitor is neuroprotective.
Fig. 1 Crohn’s disease association within the LRRK2 locus.

Fig. 1 Crohn’s disease association within the LRRK2 locus.
Fig. 2 TLR8 is aberrantly expressed on pDCs from SSc patients.

Fig. 2 TLR8 is aberrantly expressed on pDCs from SSc patients.

Similar presentations

Ads by Google